6月17日，ImmunityBio盘中上涨5.65%，报7.115美元/股，成交额3261.63万美元。此前该股因FDA处方药推广办公室（OPDP）就核心药物Anktiva营销合规问题发出正式警告信，盘中一度承压下挫。
消息面上，公司已于此前发布正式回应，明确涉事电视广告从未公开播出，并下架相关播客节目，同时承诺实施强制高管培训、扩大推广审查规程及引入外部监管顾问审计等整改措施。此外，公司持有现金及有价证券达2.428亿美元，并于近期完成1亿美元融资，Anktiva已获批用于非小细胞肺癌（NSCLC）适应症，为膀胱癌之外的首个新适应症。市场在消化合规利空后，资金逢低回补推动股价盘中反弹。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.